Protein Arrays - New technology for the proteomics era By Dr Jeffrey P. Kiplinger The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein… Read More
Unrealised wealth in the avalanche of science By Dr Benjamin P. Chen The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora's box of intellectual properties opened as a result is beyond… Read More
Outsourcing life science informatics solutions By Dr Steve Gardner The life science industry depends on information gathered from new technologies for productivity and competitive advantage in the R&D process. As more information is gathered and the systems become more complex, building and maintaining data management solutions that support rapid and… Read More
By Professor Klaus Lindpaintner Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? It is common knowledge that today’s pharmacopea – in as much as it represents enormous progress if compared with… Read More
Biologically Relevant Chemistry By Dr Stephen A. Hill A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery - using high throughput, automated in vitro and in silico methods, must become the… Read More
Implementation or algorithm? The value of Bioinformatics By Dr Christopher Hogue Recently the value of bioinformatics has been questioned. The value can be proven but are there enough qualified and professionally trained people who know how to build good bioinformatics tools? At the BIO convention in New York recently, I… Read More
Pharmaceutical Industry R&D Partnering Strategies By Riccardo Pigliucci Drug Discovery With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact 'formula for success' there are many 'success factors' that can be utilised to reduce the risk… Read More
e-R&D - The internet at work By Dr Alpheus Bingham and Dr Neil Bodick It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of e-R&D and explore… Read More
Modelling and simulation in drug development, promise and reality By Dr Mark Sale Modelling and simulation in drug development is not new. What is new is the vision for moving from a descriptive role (what happened) to a predictive and therefore decision making role. While seemingly attractive, important hurdles, both… Read More
Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury For HTS laboratories worldwide, the mission is to supply therapeutic groups in the shortest time possible with high quality hits and leads that will become drug candidates. Mounting pressure to… Read More
The promise of pharmacogenetics and pharmacogenomics By Dr Tim Peakman and Dr Steve Arlington Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready… Read More
High Throughput Screening (HTS) - Where next? By Dr Mark Beggs After approximately a decade of maturation and a three orders of magnitude increase in capabilities, High Throughput Screening (HTS) is now an established discipline within pharmaceutical discovery. But opposing stresses exist within the screening world; the resolution of which… Read More
Discovery Research in the Co-Genomic Era - Biology goes industrial By Dr Timothy Wells and Dr Georg Feger The parallel between the search for gold in the last century and drug discovery in the co-genome era is very clear. As with all gold rushes the rewards will go to the… Read More
Drug Delivery - Adding value to drug development and commercialisation By Dr Cornelis 'Cees' Winnips The importance of drug delivery as a tool to improve R&D productivity, to provide a pathway for valuable drugs to be successfully commercialised and as an expanding resource to the pharmaceutical and biotech industry, has… Read More
Do venture capitalists act as gatekeepers of new technology? By Dr June Grindley and Samantha Smart This article discusses the important role that venture capitalists and others play in helping to create companies around new technologies. We asked a number of venture capitalists, when considering funding a new company, what… Read More
High-throughput Crystallisation By Dr Sara Moran and Dr Lance Stewart With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? In an era when the development of drugs is hindered by the exorbitant costs of discovery and clinical… Read More
